blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2780326

EP2780326 - METHOD FOR INHIBITION OF DEUBIQUITINATING ACTIVITY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.11.2019
Database last updated on 02.11.2024
FormerThe patent has been granted
Status updated on  23.11.2018
FormerGrant of patent is intended
Status updated on  14.11.2018
FormerExamination is in progress
Status updated on  23.10.2018
FormerGrant of patent is intended
Status updated on  21.06.2018
FormerExamination is in progress
Status updated on  28.02.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Vivolux Ab
Uppsala Science Park
Hus Oscar II
751 83 Uppsala / SE
[2018/52]
Former [2014/39]For all designated states
Vivolux Ab
Uppsala Science Park
Hus Oscar II
751 83 Uppsala / SE
Inventor(s)01 / LINDER, Stig
Attundavägen 4
S-16858 Bromma / SE
02 / LARSSON, Rolf
Hävelvägen 2
S-75647 Uppsala / SE
 [2014/39]
Representative(s)Groth & Co. KB
P.O. Box 6107
102 32 Stockholm / SE
[2018/52]
Former [2014/39]Malmqvist, Maria
Conimar AB
P.O. Box 2086
141 02 Huddinge / SE
Application number, filing date12841677.315.10.2012
[2018/52]
WO2012SE00158
Priority number, dateSE2011000077619.10.2011         Original published format: SE 1100776
SE2012000030316.05.2012         Original published format: SE 1200303
[2014/39]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013058691
Date:25.04.2013
Language:EN
[2013/17]
Type: A1 Application with search report 
No.:EP2780326
Date:24.09.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 25.04.2013 takes the place of the publication of the European patent application.
[2014/39]
Type: B1 Patent specification 
No.:EP2780326
Date:26.12.2018
Language:EN
[2018/52]
Search report(s)International search report - published on:SE25.04.2013
(Supplementary) European search report - dispatched on:EP20.03.2015
ClassificationIPC:C07D223/08, A61K31/55, A61P35/00
[2014/39]
CPC:
C07D223/08 (EP,CN,US); A61K31/55 (EP,US); A61K9/28 (US);
A61P35/00 (EP); A61P43/00 (EP); C07D401/06 (EP,US);
C07D403/06 (EP,US); C07D409/06 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/39]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERFAHREN ZUR HEMMUNG VON DEUBIQUITINIERENDER AKTIVITÄT[2014/39]
English:METHOD FOR INHIBITION OF DEUBIQUITINATING ACTIVITY[2014/39]
French:MÉTHODE D'INHIBITION DE L'ACTIVITÉ DE DÉSUBIQUITINATION[2014/39]
Entry into regional phase05.05.2014National basic fee paid 
05.05.2014Search fee paid 
05.05.2014Designation fee(s) paid 
05.05.2014Examination fee paid 
Examination procedure05.05.2014Examination requested  [2014/39]
07.10.2015Amendment by applicant (claims and/or description)
29.01.2016Despatch of a communication from the examining division (Time limit: M04)
24.05.2016Reply to a communication from the examining division
18.07.2016Despatch of a communication from the examining division (Time limit: M04)
27.10.2016Reply to a communication from the examining division
17.02.2017Despatch of a communication from the examining division (Time limit: M04)
14.06.2017Reply to a communication from the examining division
22.12.2017Despatch of a communication from the examining division (Time limit: M04)
14.02.2018Reply to a communication from the examining division
22.06.2018Communication of intention to grant the patent
22.10.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
22.10.2018Fee for grant paid
22.10.2018Fee for publishing/printing paid
22.10.2018Receipt of the translation of the claim(s)
14.11.2018Information about intention to grant a patent
14.11.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  29.01.2016
Opposition(s)27.09.2019No opposition filed within time limit [2019/49]
Fees paidRenewal fee
27.10.2014Renewal fee patent year 03
26.10.2015Renewal fee patent year 04
27.10.2016Renewal fee patent year 05
27.10.2017Renewal fee patent year 06
30.10.2018Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL26.12.2018
CY26.12.2018
EE26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
MC26.12.2018
MK26.12.2018
MT26.12.2018
RO26.12.2018
RS26.12.2018
SI26.12.2018
SK26.12.2018
SM26.12.2018
BG26.03.2019
IS26.04.2019
[2022/31]
Former [2021/34]AL26.12.2018
CY26.12.2018
EE26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
MC26.12.2018
MT26.12.2018
RO26.12.2018
RS26.12.2018
SI26.12.2018
SK26.12.2018
SM26.12.2018
BG26.03.2019
IS26.04.2019
Former [2021/26]AL26.12.2018
CY26.12.2018
EE26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
MC26.12.2018
RO26.12.2018
RS26.12.2018
SI26.12.2018
SK26.12.2018
SM26.12.2018
BG26.03.2019
IS26.04.2019
Former [2020/29]AL26.12.2018
EE26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
MC26.12.2018
RO26.12.2018
RS26.12.2018
SI26.12.2018
SK26.12.2018
SM26.12.2018
BG26.03.2019
IS26.04.2019
Former [2020/13]AL26.12.2018
EE26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
RO26.12.2018
RS26.12.2018
SI26.12.2018
SK26.12.2018
SM26.12.2018
BG26.03.2019
IS26.04.2019
Former [2019/39]AL26.12.2018
EE26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
RO26.12.2018
RS26.12.2018
SK26.12.2018
SM26.12.2018
BG26.03.2019
IS26.04.2019
Former [2019/37]AL26.12.2018
EE26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
RO26.12.2018
RS26.12.2018
SM26.12.2018
BG26.03.2019
Former [2019/26]AL26.12.2018
HR26.12.2018
LT26.12.2018
LV26.12.2018
RS26.12.2018
BG26.03.2019
Former [2019/25]HR26.12.2018
LT26.12.2018
LV26.12.2018
RS26.12.2018
BG26.03.2019
Former [2019/23]HR26.12.2018
LT26.12.2018
LV26.12.2018
BG26.03.2019
Former [2019/22]LT26.12.2018
BG26.03.2019
Former [2019/20]LT26.12.2018
Documents cited:Search   [ ] - No further relevant documents disclosed
International search[A]WO2007007207  (YOUSSEF KHAIRIA [SA], et al);
 [A]WO2007059613  (UNIV SASKATCHEWAN [CA], et al);
 [A]WO2011005790  (UNIV OHIO STATE RES FOUND [US], et al);
 [A]  - ROMAGNOLI, R. ET AL., "Symmetrical alfa- bromoacryloylamido diaryldienone derivatives as a novel series of antiproliferative agents. Design, synthesis and biological evaluation", BIOORG. MED. CHEM. LETT., (2010), vol. 20, no. 9, pages 2733 - 2739, XP027012823
 [A]  - BERNDTSSON, M. ET AL., INDUCTION O THE LYSOSOMAL APOPTISIS PATHWAY BY INHIBITORS OF THE UBIQUITIN- PROTEASOME SYSTEM, (2009), vol. 124, no. 6, pages 1463 - 1469, XP055149446

DOI:   http://dx.doi.org/10.1002/ijc.24004
 [A]  - ALEO, E. ET AL., "Idenfitication o new compounds that trigger apoptosome-independent caspase activation and apoptosis", CANCER RES., (2006), vol. 66, no. 18, pages 9235 - 9244, XP055149448

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-06-0702
by applicant   - MASDEHORS, P ET AL., "Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin", BR J HAEMATOL, (1999), vol. 105, pages 752 - 757
    - DEMARTINO, G N ET AL., "PA700, an ATP-dependent activator of the 20 S proteasome, is an A TPase containing multiple members of a nucleotide binding protein family", J BIO CHEM, vol. 69, (1994), pages 20878 - 20884, URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed &dopt=Citation&list_uids=8063704, XP002218550
    - RECHSTEINER, M ET AL., "The multicatalytic and 26 S proteases.", J BIOL CHEM, vol. 268, (1993), pages 6065 - 6068, URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list_uids=8454582
    - ADAMS, J; KAUFFMAN, M, "Development of the proteasome inhibitor Velcade (Bortezomib)", CANCER INVEST, vol. 22, (2004), pages 304 - 311, URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve &db =PubMed&dopt=Citation&list_uids=15199612
    - ERDAL, H ET AL., "Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis", PROC NATL ACAD SCI U S A, (2005), vol. 102, pages 192 - 197
    - BERNDTSSON, M ET AL., "Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin-proteasome system", . INT J CANCER, (2009), vol. 124, doi:doi:10.1002/ijc.24004, pages 1463 - 1469, XP055149446

DOI:   http://dx.doi.org/10.1002/ijc.24004
    - LAMB, J, "The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease", SCIENCE, (2006), vol. 313, doi:doi:10.1126/science.1132939, pages 1929 - 1935, XP055253665

DOI:   http://dx.doi.org/10.1126/science.1132939
    - ADAMS, J ET AL., "Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.", BIOORG MED CHEM LETT, (1998), vol. 8, doi:doi:10.1016/S0960-894X(98)00029-8, pages 333 - 338, XP004136907

DOI:   http://dx.doi.org/10.1016/S0960-894X(98)00029-8
    - SHIBATA, T ET AL., "An endogenous electrophile that modulates the regulatory mechanism of protein turnover: inhibitory effects of 15-deoxy-Delta 12,14-prostaglandin J2 on proteasome", BIOCHEMISTRY, (2003), vol. 42, pages 13960 - 13968
    - YANG, H ET AL., "Celastrol, a triterpene extracted from the Chinese ''Thunder of God Vine, is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice", CANCER RES, (2006), vol. 66, doi:doi:10.1158/0008-5472.CAN-05-4529, pages 4758 - 4765, XP055173301

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-05-4529
    - YANG, H ET AL., "The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from ''Indian winter cherry''", MOL PHARMACOL, (2007), vol. 71, pages 426 - 437
    - MENENDEZ-BENITO, V ET AL., "Endoplasmic reticulum stress compromises the ubiquitin-proteasome system", HUM MOL GENET, (2005), vol. 14, doi:doi:10.1093/hmg/ddi312, pages 2787 - 2799, XP002555701

DOI:   http://dx.doi.org/10.1093/hmg/ddi312
    - MULLALLY, J E; FITZPATRICK, F A, "Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death", MOL PHARMACOL, vol. 62, doi:doi:10.1124/mol.62.2.351, (2002), URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed& dopt=Citation&list_uids=12130688, XP008109057

DOI:   http://dx.doi.org/10.1124/mol.62.2.351
    - GUTERMAN, A; GLICKMAN, M H, "Complementary roles for Rpn11 and Ubp6 in deubiquitination and proteolysis by the proteasome", J BIO CHEM, (2004), vol. 279, page 17291738
    - HOFMANN, R M; PICKART, C M ET AL., "Noncanonical MMS2-encoded ubiquitin conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair", CELL, (1999), vol. 96, doi:doi:10.1016/S0092-8674(00)80575-9, pages 645 - 653, XP002277040

DOI:   http://dx.doi.org/10.1016/S0092-8674(00)80575-9
    - VONG, Q P ET AL., "Chromosome alignment and segregation regulated by ubiquitination of surviving cells.", SCIENCE, (2005), vol. 310, pages 1499 - 1504
    - BORODOVSKY, A ET AL., "A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14", EMBO J, (2001), vol. 20, pages 5187 - 5196
    - LAM, Y A, "Specificity of the ubiquitin isopeptidase in the PA700 regulatory complex of 26 S proteasomes", J BIOL CHEM, vol. 272, (1997), pages 28438 - 28446, URL: http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9353303
    - VERMA, R ET AL., "Role of Rpnll metalloprotease in deubiquitination and degradation by the 26S proteasome", SCIENCE, (2002), vol. 298, doi:doi:10.1126/science.1075898, pages 611 - 615, XP002977864

DOI:   http://dx.doi.org/10.1126/science.1075898
    - YAO, T; COHEN, R E, "A cryptic protease couples deubiquitination and degradation by the proteasome", NATURE, (2002), vol. 419, pages 403 - 407
    - KRAMER, G ET AL., "Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18", CANCER RES, vol. 64, (2004), pages 1751 - 1756, URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed& dopt=Citation&list_uids=14996736
    - OLOFSSON, MH ET AL., "Specific demonstration of drug-induced tumour cell apoptosis in human xenograft models using a plasma biomarker", CANCER BIOMARKERS, vol. 5, (2009), pages 117 - 125, URL: http://www.ncbi.nlm.nih.gov/pubmed/19407366
    - REYES-TURCU, F E ET AL., "Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes", ANNU REV BIOCHEM, vol. 78, (2009), pages 363 - 397, URL: http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19489724
    - KOULICH, E, "Relative structural and functional roles of multiple deubiquitylating proteins associated with mammalian 26S proteasome", MOL BIOL CELL, (2008), vol. 19, doi:doi:10.1091/mbc.E07-10-1040, pages 1072 - 1082, XP055144936

DOI:   http://dx.doi.org/10.1091/mbc.E07-10-1040
    - BUNZ, F., "Requirement for p53 and p21 to sustain G2 arrest after DNA damage", SCIENCE, (1998), vol. 282, pages 1497 - 1501
    - PIETENPOL, J A ET AL., "Paradoxical inhibition of solid tumor cell growth by bcl2.", CANCER RES, (1994), vol. 54, pages 3714 - 3717
    - BODNAR, A G ET AL., "Extension of life-span by introduction of telomerase into normal human cells", SCIENCE, (1998), vol. 279, doi:doi:10.1126/science.279.5349.349, pages 349 - 352, XP002194331

DOI:   http://dx.doi.org/10.1126/science.279.5349.349
    - LAMB, J ET AL., "The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease", SCIENCE, (2006), vol. 313, doi:doi:10.1126/science.1132939, pages 1929 - 1935, XP055253665

DOI:   http://dx.doi.org/10.1126/science.1132939
    - ELSASSER, S ET AL., "Characterization of the proteasome using native gel electrophoresis.", METHODS ENZYMOL, (2005), vol. 398, pages 353 - 363
    - GUTERMAN, A; GLICKMAN, M H, "Complementary roles for Rpnll and Ubp6 in deubiquitination and proteolysis by the proteasome", J BIOL CHEM, (2004), vol. 279, pages 1729 - 1738
    - HAGG, M ET AL., "A novel high-through-put assay for screening of pro-apoptotic drugs", INVEST NEW DRUGS, (2002), vol. 20, pages 253 - 259
    - LINDHAGEN, E ET AL., "The fluorometric microculture cytotoxicity assay", NAT PROTOC, (2008), vol. 3, pages 1364 - 1369
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.